By Fineline Cube The World Health Organization (WHO) has lowered the age limit for Sinovac Biotech Ltd’s (NASDAQ: SVA) COVID-19 vaccine, CoronaVac, to three years old. This makes it the first vaccine on the WHO’s Emergency Use List (EUL) to be approved for such a young age group and the only one recommended for use in children aged 3 to 4.
CoronaVac’s EUL Inclusion
CoronaVac was added to the WHO’s EUL in June 2021, following a recommendation from the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) for its use in adults. The vaccine, which has been approved in over 60 countries and regions, has also received approval for pediatric use in 14 countries and regions.
Future Implications
This approval by the WHO marks a significant step in expanding the availability of COVID-19 vaccines for younger children globally. It underscores the vaccine’s safety and efficacy profile, supporting its broader use in pediatric populations.-Fineline Info & Tech